Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE)

详细信息    查看全文

• 作者：Julie K. Bower ; James S. Pankow ; Mariana Lazo ; Eric Christenson ; Ron C. Hoogeveen ; Christie M. Ballantyne ; Marc K. Halushka ; Brad C. Astor ; Elizabeth Selvin
• 关键词：Advanced glycation end products ; Reliability and validity ; Biological markers
• 刊名：Clinical Biochemistry
• 出版年：January, 2014
• 年：2014
• 卷：47
• 期：1-2
• 页码：132-134
• 全文大小：266 K

文摘

class="h4">Objectives

The soluble receptor for advanced glycation end products (sRAGE) has been implicated in the development of diabetes-related vascular complications, but the variability of concentrations of sRAGE in the blood is unknown. The objective of this study was to characterize within-person three-year variability of plasma levels of sRAGE.

class="h4">Design and methods

We measured sRAGE in plasma samples from 179 men and women in the community-based Atherosclerosis Risk in Communities (ARIC) Study at two time points, three years apart. We calculated correlation coefficients and the within-person coefficient of variation (CV_w) to characterize variability in sRAGE. We compared these estimates to total cholesterol and white blood cell count (WBC) in the same participants.

class="h4">Results

Mean sRAGE concentrations at the two time points (mean time between measurements = 2.9 years) were 1096.2 pg/mL and 990.2 pg/mL, respectively (mean difference = 鈭?#xA0;106.0 pg/mL, p-value < 0.001). The Pearson's correlation was 0.78 (Spearman's, 0.73). The intra-class correlation coefficient was 0.76 and the CV_w was 26.6%. Compared to sRAGE, Pearson's and Spearman's correlations for total cholesterol (0.76 and 0.77) and white blood cell count (0.61 and 0.72) were similar, although CV_w for both was lower (8.7% for cholesterol, 15.6% for WBC). Less than 4% of participants' values changed substantially (50% or greater) over the three-year interval.

class="h4">Conclusions

We observed that sRAGE concentrations remained relatively stable over three years. Our findings suggest that a single measure of circulating sRAGE tracks well in a community-based population and could be a useful measure in clinical and epidemiologic studies of long-term risk.